• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.

作者信息

Ji Jingran, Mitra Anupam, Camidge D Ross, Riess Jonathan W

机构信息

Department of Internal Medicine, University of California-Davis School of Medicine, Sacramento, CA.

Department of Pathology, University of California-Davis School of Medicine, Sacramento, CA.

出版信息

Clin Lung Cancer. 2021 Nov;22(6):e851-e855. doi: 10.1016/j.cllc.2021.04.008. Epub 2021 Apr 27.

DOI:10.1016/j.cllc.2021.04.008
PMID:34059475
Abstract
摘要

相似文献

1
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.ALK 重排的非小细胞肺癌中 MET 扩增导致的早期阿来替尼耐药：对克唑替尼的反应及对阿来替尼和克唑替尼的再次反应
Clin Lung Cancer. 2021 Nov;22(6):e851-e855. doi: 10.1016/j.cllc.2021.04.008. Epub 2021 Apr 27.
2
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.两种新的ALK突变介导对下一代ALK抑制剂阿来替尼的获得性耐药。
Clin Cancer Res. 2014 Nov 15;20(22):5686-96. doi: 10.1158/1078-0432.CCR-14-1511. Epub 2014 Sep 16.
3
The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.阿来替尼在间变性淋巴瘤激酶阳性非小细胞肺癌一线治疗中的应用。
Future Oncol. 2018 Aug;14(18):1875-1882. doi: 10.2217/fon-2018-0027. Epub 2018 Mar 14.
4
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.选择性ALK抑制剂阿来替尼在携带G1269A突变的ALK阳性非小细胞肺癌细胞系中的抗肿瘤活性：阿来替尼对ALK G1269A突变细胞的疗效。
Cancer Chemother Pharmacol. 2016 Mar;77(3):623-8. doi: 10.1007/s00280-016-2977-y. Epub 2016 Feb 5.
5
Alectinib: A Review in Advanced, ALK-Positive NSCLC.阿来替尼：治疗晚期、ALK 阳性 NSCLC 的研究进展。
Drugs. 2018 Aug;78(12):1247-1257. doi: 10.1007/s40265-018-0952-0.
6
Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.克唑替尼治疗既往接受艾乐替尼治疗的 EML4-ALK 融合基因复发的非小细胞肺癌：一项 II 期试验。
Thorac Cancer. 2021 Mar;12(5):643-649. doi: 10.1111/1759-7714.13825. Epub 2021 Jan 20.
7
Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation.对由G1202R溶剂前沿突变引起的间变性淋巴瘤激酶对阿来替尼和JH-VIII-157-02耐药机制的洞察。
Drug Des Devel Ther. 2018 May 9;12:1183-1193. doi: 10.2147/DDDT.S147104. eCollection 2018.
8
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).针对携带EML4-ALK融合基因的阿来替尼难治性非小细胞肺癌患者的从实验室到临床研究的方案设计（ALRIGHT/OLCSG1405）
Clin Lung Cancer. 2016 Nov;17(6):602-605. doi: 10.1016/j.cllc.2016.05.005. Epub 2016 Jun 2.
9
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.在 ALK 阳性非小细胞肺癌患者中，在用选择性 ALK 抑制剂阿来替尼治疗后，激活的 MET 充当挽救信号。
Int J Oncol. 2015 Mar;46(3):1025-30. doi: 10.3892/ijo.2014.2797. Epub 2014 Dec 15.
10
Alectinib for advanced -positive non-small-cell lung cancer.阿来替尼用于晚期ALK阳性非小细胞肺癌。
Am J Health Syst Pharm. 2018 Apr 15;75(8):515-522. doi: 10.2146/ajhp170266. Epub 2018 Feb 21.

引用本文的文献

1
Combinatorial therapy is a safe and durable treatment option in -rearranged non-small cell lung cancer with an acquired exon 14 skipping mutation mediated resistance to alectinib: a case report.联合治疗是一种安全且持久的治疗选择，用于治疗具有获得性外显子14跳跃突变介导的对阿来替尼耐药的重排非小细胞肺癌：一例报告。
Transl Lung Cancer Res. 2023 Dec 26;12(12):2558-2564. doi: 10.21037/tlcr-23-613. Epub 2023 Dec 22.
2
Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.克唑替尼治疗棘皮动物微管相关蛋白样 4-间变性淋巴瘤激酶融合基因肺癌患者耐药获得成功，可能与间充质上皮转化扩增有关。
Intern Med. 2023 Nov 1;62(21):3215-3221. doi: 10.2169/internalmedicine.1164-22. Epub 2023 Mar 15.
3
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.ALK重排非小细胞肺癌的全景：临床病理、基因组特征及治疗前景的综合综述
Cancers (Basel). 2022 Sep 29;14(19):4765. doi: 10.3390/cancers14194765.
4
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.MET 基因扩增是 ROS1+ NSCLC 对恩曲替尼产生耐药的机制。
Thorac Cancer. 2022 Nov;13(21):3032-3041. doi: 10.1111/1759-7714.14656. Epub 2022 Sep 13.
5
[Research Progress of Acquired Resistance Mediated by MET Amplification 
in Advanced Non-small Cell Lung Cancer].[MET扩增介导的晚期非小细胞肺癌获得性耐药的研究进展]
Zhongguo Fei Ai Za Zhi. 2022 Aug 20;25(8):615-621. doi: 10.3779/j.issn.1009-3419.2022.102.23.
6
Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.间变性淋巴瘤激酶重排的非小细胞肺癌治疗策略综述
Cancers (Basel). 2022 Feb 24;14(5):1184. doi: 10.3390/cancers14051184.
7
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.阿来替尼联合贝伐珠单抗治疗晚期 ALK 重排非小细胞肺癌患者的安全性和活性：一项 I/II 期研究。
ESMO Open. 2022 Feb;7(1):100342. doi: 10.1016/j.esmoop.2021.100342. Epub 2021 Dec 9.